Ketone bodies as a therapeutic for Alzheimer’s disease

Por Henderson, Samuel T.
Publicado no Neurotherapeutics (2008)

Pharmacogenetic analysis of the effects of polymorphisms in APOE, IDE and IL1B on a ketone body based therapeutic on cognition in mild to moderate Alzheimer's disease; a randomized...

Por Henderson, Samuel T, Poirier, Judes
Publicado em 2011

Melanoma of unknown primary origin presenting as a rapidly enlarging adrenal mass

Por Ejaz, Shamim, Shawa, Hassan, Henderson, Samuel Alva, Habra, Mouhammed Amir
Publicado em 2013

A ketogenic diet reduces amyloid beta 40 and 42 in a mouse model of Alzheimer's disease

Por Van der Auwera, Ingrid, Wera, Stefaan, Van Leuven, Fred, Henderson, Samuel T
Publicado em 2005

Hypometabolism as a therapeutic target in Alzheimer's disease

Por Costantini, Lauren C, Barr, Linda J, Vogel, Janet L, Henderson, Samuel T
Publicado em 2008

Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer's disease: a randomized, double-blind, placebo-controlled, multicenter trial

Por Henderson, Samuel T, Vogel, Janet L, Barr, Linda J, Garvin, Fiona, Jones, Julie J, Costantini, Lauren C
Publicado em 2009